Targeting the ATM-TRMT10A-BRCA1 axis confers synthetic lethality to PARP inhibition in metastatic castration-resistant prostate cancer | Science Advances
Targeting TRMT10A boosts PARP inhibitor effectiveness in advanced prostate cancers lacking BRCA mutations.
